Enanta Pharma Files 8-K for Undisclosed 'Other Event'
Ticker: ENTA · Form: 8-K · Filed: Mar 26, 2026 · CIK: 0001177648
| Field | Detail |
|---|---|
| Company | Enanta Pharmaceuticals Inc (ENTA) |
| Form Type | 8-K |
| Filed Date | Mar 26, 2026 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: other-event, regulatory-filing
TL;DR
**Enanta filed an 8-K for an undisclosed 'Other Event' on March 20, 2026; details are pending.**
AI Summary
Enanta Pharmaceuticals Inc. filed an 8-K on March 26, 2026, reporting an "Other Event" under Item 8.01 related to its period of report ending March 20, 2026. While the filing itself doesn't detail the specific event, it signals that something noteworthy occurred that the company deemed important enough to disclose. For investors, this matters because an undisclosed 'Other Event' could range from a minor operational update to a significant development in their pharmaceutical pipeline, potentially impacting future stock performance depending on the nature of the event.
Why It Matters
This filing indicates a significant, yet currently unspecified, event occurred for Enanta Pharmaceuticals, which could influence its operations, financial health, or strategic direction. Investors need to monitor for further details to understand the potential impact on the company's valuation.
Risk Assessment
Risk Level: medium — The risk is medium because an undisclosed 'Other Event' could be positive or negative, creating uncertainty until more information is released.
Analyst Insight
A smart investor would add Enanta Pharmaceuticals to their watchlist and set up alerts for any subsequent filings or press releases that detail the 'Other Event' mentioned in this 8-K, as the nature of this event could significantly impact the stock.
Key Numbers
- 2026-03-26 — Filing Date (The date the 8-K was filed with the SEC.)
- 2026-03-20 — Period of Report (The date to which the reported event pertains.)
- Item 8.01 — Reported Item (The specific item under which the event was disclosed, indicating an 'Other Event'.)
- 9 — Number of Documents (The total number of documents included in the filing.)
Key Players & Entities
- ENANTA PHARMACEUTICALS INC (company) — the filer of the 8-K
- 0001177648 (company) — the CIK of Enanta Pharmaceuticals Inc.
- 0001193125-26-125113 (dollar_amount) — the SEC Accession No. for the filing
- 2026-03-26 (dollar_amount) — the filing and acceptance date
- 2026-03-20 (dollar_amount) — the period of report date
Forward-Looking Statements
- Enanta Pharmaceuticals will release more details about the 'Other Event' within the next 30 days. (ENANTA PHARMACEUTICALS INC) — medium confidence, target: 2026-04-26
FAQ
What specific event did Enanta Pharmaceuticals Inc. report in this 8-K filing?
The filing indicates an 'Other Event' under Item 8.01, but the specific details of the event are not provided within the summary information of the 8-K itself. Further examination of the attached documents (e.g., enta-20260320.htm) would be necessary to ascertain the nature of the event.
When was this 8-K filing submitted and accepted by the SEC?
The 8-K filing was submitted and accepted by the SEC on March 26, 2026, at 08:00:07.
What is the 'Period of Report' for the event disclosed in this 8-K?
The 'Period of Report' for the event disclosed in this 8-K is March 20, 2026.
Under which item of Form 8-K was this event reported?
This event was reported under Item 8.01, which is designated for 'Other Events'.
What is the CIK number for Enanta Pharmaceuticals Inc.?
The CIK number for Enanta Pharmaceuticals Inc. is 0001177648.
Filing Stats: 436 words · 2 min read · ~1 pages · Grade level 10.4 · Accepted 2026-03-26 08:00:07
Key Financial Figures
- $0.01 — ch registered Common Stock, par value $0.01 per share ENTA Nasdaq Global Select
Filing Documents
- enta-20260320.htm (8-K) — 39KB
- 0001193125-26-125113.txt ( ) — 142KB
- enta-20260320.xsd (EX-101.SCH) — 24KB
- enta-20260320_htm.xml (XML) — 5KB
01 Other Events
Item 8.01 Other Events. As previously disclosed by Enanta Pharmaceuticals, Inc. (the "Company"), on February 3, 2025, the Company filed a notice of appeal with the United States Court of Appeals for the Federal Circuit relating to its suit against Pfizer Inc. seeking damages for infringement of U.S. Patent No. 11,358,953 in the manufacture, use, and sale of Pfizer's COVID-19 antiviral, Paxlovid (nirmatrelvir tablets; ritonavir tablets). On March 20, 2026, the Federal Circuit scheduled oral argument for the appeal to be held on May 11, 2026.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ENANTA PHARMACEUTICALS, INC. Date: March 26, 2026 By: /s/ Jay R. Luly, Ph.D. Jay R. Luly, Ph.D. President and Chief Executive Officer